Celldex Therapeutics Announces Proposed Public Offering of Common Stock for Continued Product Development
HAMPTON, N.J. Nov 07, 2023 - Celldex Therapeutics, Inc.(Nasdaq: CLDX), a leading biopharmaceutical company, has recently announced its plans to offer and sell shares of its common stock in an underwritten public offering, subject to market conditions.The company intends to grant the underwriters an option to purchase an additional 15% of the shares offered.All the shares of common stock being offered will come directly from Celldex Therapeutics.
The net proceeds from this public offering will primarily be used to support the ongoing clinical and preclinical development of Celldex’s diverse product candidates.This includes the advancement of barzolvolimab, the company’s leading development candidate, as well as the expansion and development of their bispecific antibody platform and clinical pipeline.
Additionally, the funds raised are expected to support Celldex Therapeutics’ efforts in developing new clinical pipeline products.The company aims to expand its product offerings and further bolster its position in the biopharmaceutical industry.The net proceeds will be allocated towards various research and development activities, enabling Celldex to pursue its mission of delivering innovative therapies to patients.
The final terms of the offering, including the size and pricing, will depend on market conditions at the time of pricing.As with any public offering, completion is subject to investor demand and the fulfillment of specific conditions.There is no guarantee as to whether or when the offering will be completed or the actual size and terms of the offering.
As of now, Celldex Therapeutics has 47.2 million shares outstanding, and the current market price per share stands at $29.02.These figures provide context in understanding the potential impact of the proposed public offering on Celldex’s capital structure.
In conclusion, Celldex Therapeutics’ announcement of a proposed public offering of common stock reflects the company’s commitment to advancing its robust pipeline of innovative therapies.The offering aims to provide the necessary financial resources to continue clinical and preclinical development, expand their product portfolio, and drive the future growth and success of Celldex Therapeutics.
Comments